Banner: investors

News Releases

PURE Bioscience Establishes Scientific Advisory Board to Leverage SDC-Based Antimicrobial Technologies to Ensure a Safer Food Supply

March 02, 2016

SAN DIEGO (March 2, 2016) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that is has formed a Scientific Advisory Board and that it will be led by James L. Marsden, Ph.D., Emeritus Distinguished Professor–Food Safety and Security Kansas State University.

The mission of the Board is to leverage PURE’s SDC-based technologies, PURE® Hard Surface and PURE Control®, to help ensure a safer food supply. The Advisory Board will include scientists with expertise in food science, food safety, food service and food processing and will assist PURE as the Company continues to develop applications for, and commercialize, its patented EPA and FDA approved SDC antimicrobial as a non-toxic, leading-edge food safety solution. SDC has proven superior in killing pathogens causing foodborne illness including Salmonella, E. coli, Listeria and Norovirus.

Hank R. Lambert, CEO of PURE said, “Now that we have recently attained FDA approvals for use of PURE Control as a direct food contact processing aid for both fresh produce and raw poultry, our Company is at an important inflection point. We’ve established a Scientific Advisory Board to deepen our resources and advance our corporate initiatives as we establish our superior SDC antimicrobial technology as a solution to further the cause of a safer food supply.”

Since 2013, as a consultant to PURE, Dr. Marsden has made important contributions to help guide the Company’s product development and regulatory initiatives of its two antimicrobial products, PURE Control (FDA approved direct food contact processing aid for fresh produce and for raw poultry) and PURE Hard Surface (EPA registered food contact surface sanitizer and environmental disinfectant).

The members of the Advisory Board will provide guidance for future FDA, USDA and other regulatory applications and submissions; including the preparation of protocols, application testing in pilot plant environments, input on summary reports and future white papers.

In December, 2014, Dr. Marsden authored a white paper detailing the successful remediation of Listeria contamination in a food processing facility. The decontamination of the plant was achieved by utilizing a cleaning and sanitizing program incorporating PURE Hard Surface disinfectant and the plant was cleared by the FDA to reopen and return to online food production.

About PURE Bioscience, Inc. 

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

 

Forward-looking Statements   

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace; the Company’s ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw poultry and raw meat processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2015 and its Form 10-Q for the first quarter ended October 31, 2015. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. 

 

 

Contacts:

Hank Lambert, CEO                           Terri MacInnis, VP of IR                      Tom Hemingway       

PURE Bioscience, Inc.                         Bibicoff + MacInnis, Inc.                     Redwood Investment Group

619-596-8600 ext.103                         818-379-8500                                       714-978-4425

hlambert@purebio.com                     terri@bibimac.com                            tomh@redwoodfin.com